Update on antiphospholipid syndrome.
This review addresses new clinical issues (revealed at the 2006 Sydney update of the 1999 Sapporo Classification criteria; cardiac, renal, and multiple sclerosis-like disease; catastrophic syndrome), mechanisms of action of antiphospholipid antibody (very likely complement mediated), current therapies (moderate dose warfarin recommended for prophylaxis, aspirin not recommended for primary prophylaxis), and potential new therapies.
Preliminary classification criteria for antiphospholipid syndrome (APS) were determined in a post-conference workshop following the 1998 Eighth International Symposium on Antiphospholipid Antibodies. (1) While clinical associations had been recognized between antiphospholipid (aPL) antibodies and, for example, events of vascular thrombosis and pregnancy loss, causation mechanisms are not well understood. This and awareness regarding the variety of disciplines contributing to the developing knowledgebase of aPls, along with the need to clarify the current bases for criteria, resulted in a consensus statement published in 1999. These new tentative clinical criteria became a basis from which further clinical and investigative work on APS could proceed more soundly. The update below addresses three aspects of APS, to include the new clinical issues, mechanisms of action, treatment recommendations, and subsequent revisions.
New Clinical Issues
The preliminary criteria for APS were revised in Sydney, Australia in 2004 (published in 2006). (2) The differences between the original and the revised criteria were: 1. the addition of exclusionary criteria, in particular, older age (males 55 and older, females 65 and older, because of competing alternative causes for thromboembolic disease in older age groups); 2. an increase in the required interval from 6 to 12 weeks, during which two consecutive tests be positive (because infection-induced auto-antibodies can be positive for more than 6 weeks); and 3. the addition, for individual diagnosis (but not for population studies) of clinical and laboratory criteria that are very uncommon, alternatively explained, or generally unavailable, except in specialized laboratories. These findings include aPL antibody-associated cardiac valve disease, livedo, thrombocytopenia, and nephropathy, as well as IgA antibody, antibody to phosphatidylserine, and other less well characterized antigens. Kaul and colleagues found elements of the revised clinical criteria to be present in 6% to 25% of patients identified by thromboembolic disease, but much less frequently in patients identified by pregnancy morbidity. IgA antibodies were not commonly present but other antibodies were. (3)
A European group recently has argued that a test for lupus anticoagulant is more valid than the enzyme linked immunosorbent assay (ELISA) for anticardiolipin and should constitute the primary criterion for diagnosis of APS. (4) Reasons to reject this argument are: 1. its proponents are primarily hematologists, with a vested interest in doing the tests; 2. consensus already exists that lupus anticoagulant is a more specific but far less sensitive test than is ELISA for anticardiolipin; and 3. the ELISA is far more reproducible and, unlike the lupus anticoagulant test, can be reliably repeated on frozen or shipped specimens. In tests of the reproducibility of the standard ELISA, Erkan and coworkers demonstrated a comfortable degree of consistency, even using commercial laboratories. (5)
Thrombotic microangiopathy is an uncommon but devastating manifestation of long-standing APS. It presents as bland proteinuria with hypertension and progresses slowly, but can lead to renal failure. The multiple sclerosis-like presentation of APS mostly reflects cognitive dysfunction and abnormal MRI. In a cross-sectional study of patients with APS, aPL without syndrome, systemic lupus erythematosus (SLE) and aPL antibody, unclassified autoimmune disease with aPL antibody, and multiple sclerosis patients with aPL antibody, Tenedios found chorea, migraine, seizure, and dysarthria more frequent in APS, while optic neuritis, bowel and bladder abnormalities, and gait disturbances were more common in multiple sclerosis. Distinctions could be made among the MRI abnormalities (in APS, abnormalities are nonenhancing with gadolinium); antibody tests are generally strongly positive in patients with APS and less so, or low-positive in patients with multiple sclerosis (Table 1). Cardiac thrombi and cardiac valve disease both occur in APS and can be responsible for embolic disease. In SLE, Libman-Sacks valvular abnormalities are associated with aPL antibody. (6,7) The catastrophic syndrome remains a rare but highly lethal manifestation of the syndrome. (8,9) In some cases, occlusion of multiple vessels occur, beginning at the microvascular level rather than at the macrovascular one. (10) Surgery and pregnancy appear to trigger thrombotic events; arterial events are more likely in hypertensive patients and in smokers. (11)
Mechanisms of Action
Many hypotheses have been offered to explain how aPL antibody triggers or is associated with thrombotic events. Leading hypotheses include the ability of this antibody (which likely results from cross reactivity with a common viral infection in a genetically prepared host) to induce tissue factor in endothelial cells and monocytes, to induce platelet aggregation, and to induce endothelial cell adhesion receptors, or to activate complement. (11) A particularly compelling hypothesis is supported by animal models in which full anticoagulation with the noncomplement activating anticoagulants hirudin or fondaparinux cannot prevent pregnancy loss or thrombosis; however, sub-anticoagulant doses of heparin, complement deficiency, or complement inactivation by other mechanisms are able to do so. This strongly argues that the first and critical step of aPL antibody-associated thrombosis or fetal loss is complement-mediated and is not a coagulation step. (12,13) New therapies in the future may address this issue.
Treatment in 2008
Warfarin remains the mainstay of treatment for the thrombotic manifestations of the syndrome, and heparin for the pregnancy manifestations. Nonetheless, no data indicate that anticoagulation is beneficial for thrombotic microangiopathy, valvular heart disease, livedo reticularis, leg ulcers, or MRI abnormalities associated with cognitive dysfunction. Two high dose and low dose-controlled clinical trials strongly support the idea that a target international normalized ratio (INR) of 2.5 is sufficient for the treatment of most patients. (14,15) A systematic retrospective review, however, took the position that for secondary prophylaxis a higher dose was both more effective and more likely to lead to hemorrhagic complications. (16) Two reviews reached remarkable consensus on treatment recommendations. (17,18)
Recent data indicate that genetic variation in warfarin metabolism may be important in dose adjustment, (19) and gene expression patterns among bearers of aPL antibody may predict clinical phenotype (specifically, whether or not thrombosis results). (20) Most authorities agree that lifelong anticoagulation is indicated, but questions have arisen whether in patients with triggered thromboses, those antibodies disappear, or for patients who no longer have trigger risks, whether they might eventually, safely be able to discontinue anticoagulation.
With regard to primary prophylaxis, a randomized 3-year prospective controlled trial of aspirin versus placebo indicated there was no benefit of aspirin for persons found to carry a moderate to high titer aPL antibody but who had no prior thromboses. (21) By contrast, a retrospective 10-year study, using low titer antibody positive persons, but which did not verify dosing, argued that aspirin is beneficial. (22) No definitive statement yet exists regarding the efficacy of other agents such as clopidogrel, low molecular weight heparin, or alternatives for thromboses prevention.
Some investigators advocate the use of hydroxychloroquine and statin drugs; biological theories supporting the recommendations of clinical trials demonstrating efficacy do not exist. Case reports suggest that rituximab may be beneficial, as may intravenous immunoglobulin in the catastrophic syndrome. Trials are underway to examine these possibilities. In particular, a trial is underway at this institution to test whether rituximab could be of benefit in patients with anticoagulant resistant manifestations, including thrombotic microangiopathy, valvular heart disease, thrombocytopenia, and cognitive dysfunction.
None of the authors have a financial or proprietary interest in the subject matter or materials discussed, including, but not limited to, employment, consultancies, stock ownership, honoraria, and paid expert testimony.
(1.) Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 1999 Jul;42(7):1309-11.
(2.) Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update to the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost. 2006;4:295-306.
(3.) Kaul M, Erkan D, Sammaritano L, Lockshin MD. An assessment of the 2006 revised antiphospholipid syndrome classification criteria, Ann Rheum Dis. 2007;66:927-30.
(4.) Galli M, Reber G, de Moerloose P, de Groot PG. Invitation to debate on the serological criteria that define antiphospholipid syndrome. J Thromb Haemost. 2008;6:399-401.
(5.) Erkan D, Derksen WJ, Kaplan V, et al. Real world experience with antiphospholipid antibody tests: how stable are results over time? Ann Rheum Dis. 2005;64:1321-5. Epub 2005 Feb 24.
(6.) Erkan D, Erel H, Yazici Y, Prince MR. The role of cardiac magnetic resonance imaging in antiphospholipid syndrome. J Rheum. 2002, 29:2558-9.
(7.) Farzaneh-Far A, Roman MJ, Lockshin MD, et al. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum. 2006;54.3918-25.
(8.) Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev. 2006 Dec;6(2):98-103. Epub 2006 Jul 21.
(9.) Bucciarelli S, Espinosa G, Cervera R, et al. European Forum on Antiphospholipid Antibodies. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum. 2006 Aug;54(8):2568-76.
(10.) Erkan D, Leibowitz E, Berman J, Lockshin MD. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations. J Rheumatol. 2002;29(4):843-9.
(11.) Erkan D, Yazici Y, Peterson MG, et al. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology. 2002;41:924-9.
(12.) Salmon J, de Groot P. Pathogenic role of antiphospholipid antibodies, Lupus. 2008;17:405-11.
(13.) Girardi G, Yarilin D, Thurman JM, et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med. 2006 Sep 4;203(9):2165-75. Epub 2006 Aug 21.
(14.) Salmon JE, Girardi G, Lockshin MD. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol. 2007 Mar;3(3):140-7.
(15.) Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003 Sep 18;349(12):1133-8.
(16.) Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005 May;3(5):848-53.
(17.) Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum. 2007;57:148-795.
(18.) Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006 Mar 1;295(9):1050-7.
(19.) Erkan D, Lockshin M. Antiphospholipid syndrome. Curr Opin Rheumatol. 2006 May;18(3):242-8.
(20.) Schwarz UI, Ritchie MD, Bradford et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358:999-1008.
(21.) Potti A, Bild A, Dressman HK, et al. Gene expression patterns predict phenotypes of immune mediated thrombosis. Blood. 2006;107:1391-6.
(22.) Erkan D, Harrison MJ, Levy R, et al. A randomized double-blind placebo-controlled trial in asymptomatic antiphospholipid antibody positive individuals. Arthritis Rheum. 2007;56:238-291.
Michael D. Lockshin, M.D
Michael D. Lockshin, M.D., is Professor of Medicine and Obstetrics-Gynecology, Weill Medical College of Cornell University, and an Attending at the Hospital for Special Surgery and the New York Presbyterian Hospital, New York, New York.
Correspondence: Michael D. Lockshin, M.D., 535 East 70th Street, New York, New York 10021; email@example.com.
Table l Distinctions Between Antiphospholipid Antibody-Associated Multiple Sclerosis-like Syndrome and Multiple Sclerosis * Item APS APL APS/SLE Number 30 20 20 Symptoms Chorea, None Cognitive pseudotumor, dysfunction, migraine, seizure, numbness dysarthria MRI Small UBOs, None Like APS nonenhancing, CVA aCL/[beta]2GP1 High High High Lupus anticoagulant Present Other APS symptoms Present Present Present Item Unclassified Multiple Sclerosis Number 20 20 Symptoms Ataxia, TIA, Numbness, optic headache, neuritis, bladder confusion and gait disturbance, paresthesias MRI Like APS Large UBOs, enhancing, confluent aCL/[beta]2GP1 Variable Low Lupus anticoagulant Present Absent Other APS symptoms Absent Rare * Unpublished data from Tenedios F, Apatoff B, and Lockshin M. APS, antiphospholipid syndrome; aPL, antiphospholipid antibody without thrombotic events; SLE, systemic lupus erythematosus; CVA, cerebrovascular accident; UBO "unknown bright object," hyperintense lesion on MRI; TIA, transient ischemic attack.
|Printer friendly Cite/link Email Feedback|
|Author:||Lockshin, Michael D.|
|Publication:||Bulletin of the NYU Hospital for Joint Diseases|
|Article Type:||Clinical report|
|Date:||Sep 1, 2008|
|Previous Article:||Lupus nephritis: histology, diagnosis, and treatment.|
|Next Article:||Systemic sclerosis: an update.|